According to a study which was published in The New England Journal of Medicine, Eli Lilly and Company’s experimental drug could slow the cognitive decline of those suffering from Alzheimer’s disease. The downside, however, is that the drug is intravenous, not in a pill form. An early clinical trial studied 257 with early signs of Alzheimer’s. Of those, 131 received the drug and 126 received a placebo. Researchers found that those who got the drug showed a slowing of cognitive decline and the ability to perform daily functions by 32% after 76 weeks, compared to those who received a placebo. The study also looked at the build up of amyloid beta plaque and tau proteins, both of which are signs of Alzheimer’s disease. At the 52-week mark in the Phase 2 Clinical Trial, almost 60% of participants who received the drug were amyloid-negative. At week 76, amyloid plaque levels decreased by 85% in those taking the drug versus those who received the placebo. Regular readers of my blog know that both my father and grandmother had this terrible disease when they passed away. There are great people at our local chapter of Alzheimer’s Association in Ryan’s Ranch. They also have a 24-hour hotline if you need support at 800-272-3900.
President Joe Biden made a campaign promise to limit big pharma’s price increases on prescription drugs to no more than inflation—and now is the time to make good on that promise. A new study found that half of all Part D-covered drugs had list price increases above inflation between 2018 and 2019, and the median list price was rose 6.4%, or 3.5x the rate of inflation. List prices increased by 10% or more for 14% of all Part D-covered drugs during the same time period. Another 36% had price increases above the price of inflation but below 10%. Enough is enough!
The Food & Drug Administration FDA is taking another look at aducanumab, a potential new drug for treating Alzheimer’s Disease and dementia. The drug candidate will undergo an additional three months of review after a panel of experts in November recommended against approving the drug. Biogen and Eisai partnered on the development of the drug and delivered new data to the FDA, triggering the prolonged review time. An independent committee of experts had criticism of both the drug’s merits and the interpretation of data by FDA scientists. Biogen said the data from one clinical trial showed a slowing in cognitive decline compared to study participants who received a placebo. In the second clinical trial, the drug failed to show a benefit. However, Biogen says it is likely because fewer patients received the higher dosage. Regular readers of my blog know that both my father and grandmother had this terrible disease when they passed away. There are great people at our local chapter of Alzheimer’s Association in Ryan’s Ranch. They also have a 24-hour hotline if you need support at 800-272-3900.